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Abstract
Bloodstream infections are associated with high morbidity and mortality with rates varying
from 10–25% and higher. Appropriate and timely onset of antibiotic therapy influences the
prognosis of these patients. It requires the diagnostic accuracy which is not afforded by cur-
rent gold standards such as blood culture. Moreover, the time from blood sampling to blood
culture results is a key determinant of reducing mortality. No established biomarkers exist
which can differentiate bloodstream infections from other systemic inflammatory conditions.
This calls for studies on biomarkers potential of molecular profiling of plasma as it is affected
most by the molecular changes accompanying bloodstream infections. N-glycosylation is a
post-translational modification which is very sensitive to changes in physiology. Here we
have performed targeted quantitative N-glycoproteomics from plasma samples of patients
with confirmed positive blood culture together with age and sex matched febrile controls
with negative blood culture reports. Three hundred and sixty eight potential N-glycopeptides
were quantified by mass spectrometry and 149 were further selected for identification.
Twenty four N-glycopeptides were identified with high confidence together with elucidation
of the peptide sequence, N-glycosylation site, glycan composition and proposed glycan
structures. Principal component analysis, orthogonal projections to latent structures-dis-
criminant analysis (S-Plot) and self-organizing maps clustering among other statistical
methods were employed to analyze the data. These methods gave us clear separation of
the two patient classes. We propose high-confidence N-glycopeptides which have the
power to separate the bloodstream infections from blood culture negative febrile patients
and shed light on host response during bacteremia. Data are available via ProteomeX-
change with identifier PXD009048.
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Introduction
Bloodstream infections are an increasing problem which is correlated to high morbidity
and mortality[1]. Bacteremic infections even today are associated with high mortality which
depending on the causative agent varies between 10–25% but in most severe cases may be
significantly higher [1, 2]. Early diagnosis and onset of effective antibiotic therapy is the key
in reducing the mortality in bloodstream bacterial infections[3]. However, antibiotic treat-
ment in bacteremic infections has to be initiated empirically based on clinical findings
viewed against unspecific laboratory markers of inflammation. Plasma levels of circulated
inflammatory mediators such as C-reactive protein (CRP), procalcitonin (PCT) and inter-
leukin-6 (IL-6) have been suggested to predict the bacterial bloodstream infections[4–6].
However, these biomarkers are not sufficiently sensitive or specific because they are ele-
vated in other non-infectious including trauma and inflammation for example due to a
rheumatological disease[7–9]. The golden standard in diagnosis of bacteremic infections is
blood culture which is far too slow for early clinical decisions as the results have to be waited
for 24 to 48 hours. This results in unnecessary antibiotic therapies with risk for resistance
development. On the other hand, those patients with a true positive blood culture may not
be treated efficiently enough. Novel markers specific for bloodstream infections might help
to direct therapy to right patients from the very early onset of the disease when it would be
most desperately needed.
Plasma proteomics as well as glycoproteomics has been suggested to be an important
source of biomarkers for systemic diseases [10–12]. Our study on the subject was able to
suggest multiple protein markers of bloodstream infection[12]. Post-translational modifica-
tion (PTM) of proteins increase the repertoire of functions proteins can perform. One of
the most abundant PTM, glycosylation is found in about 50% of human proteins and cova-
lent addition of glycan residues to asparagine is called N-glycosylation. Changes in level or
sites of N-glycosylation can alter the physiological function of proteins or lead to patho-
physiological processes. N-glycosylation machinery is very sensitive to changes in physiol-
ogy caused by pathological processes such as cancer or microbial infection[11, 13]. These
changes can be detected and quantified to work as detection and monitoring biomarkers of
pathological processes.
There are abundant changes in plasma proteins due to severe inflammatory reactions.
Glycoproteomic analyses have been shown to discern survivors from non-survivors due
to sepsis in ICU [11]. We have previously developed a quantitative N-glycoproteomics
workflow in a series of studies[14–17]. This workflow can lead to quantification of N-glyco-
peptides and at the same time establish their peptide sequence, glycan composition and pro-
posed glycan structure[14–17]. In the current study, extending our proteomic findings[12],
we utilize this workflow to quantify the N-glycopeptides in samples from patients having a
confirmed bloodstream infection and age and sex matched febrile non-bacteremic controls.
The quantification was followed by stringent statistical analyses such as ANOVA, Principal
component analysis (PCA) and Orthogonal projections to latent structures-discriminant
analysis (OPLS-DA). OPLS-DA analysis gave us the S-Plot which was used to find the sig-
nificantly differing proteins among the bloodstream infection individuals and controls in
bacterial strain-independent manner. Three hundred sixty eight potential N-glycopeptide
ions were quantified and 149 were selected to be fragmented and identified. We identified
24 N-glycopeptides along with their peptide sequence, N-glycosylation site, glycan compo-
sition and proposed glycan structures. As shown by various statistical analyses, these N-gly-
copeptide ions were able to classify bloodstream infected cases from febrile non-bacteremic
controls.
Quantitative N-glycoproteomics of bacteremia plasma
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Results
Overview
The whole workflow utilized interconnected steps in a sequential manner which is presented
in Fig 1. Plasma samples from ten blood culture confirmed cases of bloodstream infection and
ten age and sex matched febrile controls were obtained as described in methods. These samples
were processed to enrich N-glycopeptides which were analyzed in two sequential but separate
steps: Step 1: HDMSE to quantify the precursor ions (m/z) and; Step 2: LC-MS/MS to identify
the N-glycopeptides as well as to establish the peptide sequence, glycan composition and pro-
posed glycan structure for those precursors which differed significantly between the cases and
controls. Publicly available software package GlycopepitdeId was used for searching the
LC-MS/MS spectra peak list for step 2.
Patients
Twenty febrile patients coming to Peijas hospital (Vantaa, Finland) were divided into two
groups based on blood culture findings (blood culture positive and blood culture negative).
Blood culture positive group included 8 men and 2 women and was designated “cases” while
Fig 1. Overview of the workflow. The complete workflow starting form plasma samples to quantification and identification of
N-glycopeptides is summarized here.
https://doi.org/10.1371/journal.pone.0195006.g001
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10 blood culture negative patients (age and sex matched) were designated as controls. Blood
cultures identified bacterial species were Escherichia coli (4 samples), Streptococcus pneumoniae
(2 samples), coagulase-negative Staphylococcus (2 samples), Staphylococcus epidermidis and
Streptococcus viridans (1 sample each). Plasma C-reactive protein (CRP) levels among cases
were 12–399 mg/L and febrile controls had levels of CRP ranging from 13–101 mg/L. Among
the control patients, four patients presented with no verified infection and were not treated
with antibiotics. Two patients had pyelonephritis and four patients presented with a respira-
tory infection which was supposed to be of viral origin. However, three of the controls suppos-
edly having respiratory viral infection received oral antibiotics (doxycycline, cephalexin or co-
amoxyclavulanate). All HDMSE runs performed well in terms of chromatographic perfor-
mance and alignment and therefore no sample was excluded from analysis.
HDMSE and statistical analysis
N-glycopeptides were enriched from tryptic digests of albumin-depleted total plasma proteins
utilizing a mixture of four different lectins. Concanavalin A (Con A), Sambucus nigra aggluti-
nin (SNA), Lens culinaris (LCA) and Aleuria aurantia lectin (AAL) slurries were mixed in a
ratio of 5:3:3:1 and N-glycopeptides were enriched from tryptic digests mixture. This ratio of
lectin was empirically determined (data not shown). The presence of N-glycopeptides was ver-
ified in the high energy function of MSE runs by characteristic N-glycan fragmentation ions
(m/z values of 138, 204, 366.14, 657.23 etc.). Every LC-MS run was performed in triplicate.
Raw data was imported into Progenesis and peak picking and alignment was performed as
described in the methods. Potential glycopeptides were selected for further analysis with fol-
lowing criteria: requirement for charge of +3 to +5 and intensity of at least 104. Three hundred
sixty eight precursor ions matched these criteria and they were quantified (Table A in S2 File).
T-test was performed on this data and the resulting p values are given in Table A in S2 File.
This quantitative data was used for performing principal component analysis (PCA) which is
shown in Fig 2.
PCA based on 368 quantified ions gave separation of cases vs controls. However, one case
was segregating from the other cases and clustering with the control class (Fig 2). To further
identify the features (Ions) which can classify the cases vs controls, the data was used to per-
form the orthogonal projections to latent structures-discriminant analysis (OPLS-DA). This
modeling of the data gave us the S-Plot which is shown in Fig 3.
Fig 2. Principal component analysis. Principal component analysis of all the quantified potential N-glycopeptide ions was performed with the Progenesis
software. Blue circles represent blood culture positive cases while the purple circles are febrile controls. X-axis is principal component 1 and Y-axis is
principal component 2.
https://doi.org/10.1371/journal.pone.0195006.g002
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OPLS-DA is a modeling technique which can identify the classifying features of two groups
of samples representing predictive variance. These features (ions) can then be used to classify
the sample groups into their respective classes (for example cases vs controls). Forty one ions
were selected as being significantly different between the cases and controls (p(Corr) values
given in Table B in S2 File). When we used S-plot ions for running PCA analysis, we were able
to completely separate the cases and controls including the one case sample (Case 10) which
was not separating that well with other analyses (Figure A in S1 File). These S-Plot ions corre-
spond to a panel which can be used in targeted assays to predict the blood culture positive
patients and separate them from other febrile patients however further studies are needed in
this regard.
Identification of N-glycopeptides
Based on S-Plot, T-test p values and intensity in HDMSE runs, 149 ions were selected to be
fragmented for identifying the peptide sequence, N-glycosylation site, N-glycan sequence and
proposed N-glycan structure. Out of these 149 ions, we were able to confidently identify 24
glycopeptide ions with a false discovery rate (FDR) of 3.84%. These glycopeptides are pre-
sented in Table 1. The median percentage coefficient of variation for all triplicate run was
4.011% (for t-test p value <0.05). This suggests robust technical reproducibility of the runs.
Cases had within-group median %CV at 65.54%, and controls 50.26% (t-test p value <0.05).
This suggests that inter-individual variability of N-glycopeptides is high which is however, in
accordance with previous reports [18].
These 24 glycopeptides belonged to 8 different proteins. Ten unique peptides were found
containing 11 N-glycosylation consensus site (NXS/T/C, where X is any amino acid except
Fig 3. S-plot. Orthogonal projections to latent structures-discriminant analysis modeling was performed with the software EZInfo 3.0 and resulting S-plot is
shown here. X-axis is loadings and Y-axis is correlation. Minus half of the figure is proteins having higher expression in cases while plus half is the proteins
having higher expression in controls.
https://doi.org/10.1371/journal.pone.0195006.g003
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proline). One peptide contained two consensus sites and the occupancy of either site was
ambiguous. Peptide identification scores ranged from 21.75 to 50.18. Data-dependent acquisi-
tion LC-MS was performed in a targeted way to identify the glycopeptide ions. We have
employed this N-glycopeptide identification workflow in our previous studies in different set-
tings and set of samples[15–17].
Glycan compositions and proposed structures
Glycan scores of these 24 N-glycopeptides ranged from 6.21 to 50.66 while overall glycopeptide
scores were found to be from 28.54 to 85.11. Out of the 24 glycopeptides which were identified
by targeted N-glycoproteomics, nineteen glycan compositions were found to be sialylated.
Twenty glycan structures for as many numbers of glycopeptides were proposed while 4 com-
positions were constructed denovo. For detailed description of how these compositions and
structures are generated, see methods and our previous studies[14–17]. Twelve sialylated gly-
copeptides were bi-antennary as can be claimed by number of sialic acid as typically N-glycan
branch is end capped with sialic acid and polysialic acid is very rare. Proposed structure
S2H5N4 (S: Sialic acid, H: Hexose, N: HexNAc, Accession number: G90099GV, Glycome-DB)
was found on five glycopeptides. One structure was found to be tri antennary (S3H6N5) while
others were mono-sialylated mono or bi-antennary structures. Out of the four non-sialylated
glycopeptides, one was constructed denovo, two were core fucosylated while one had a poten-
tial LacDiNAc motif. In total, six structures were proposed for fucosylated glycopeptides. Larg-
est microheterogeneity was found for Immunoglboulin-A heavy chain. For IgA heavy chain
peptide (LSLHRPALEDLLLGSEANLTCTLTGLR), six different glycan compositions were
found attached to the same glycosylation site (Fig 4).
These glycan compositions and structures were obtained by matching to the database (Gly-
comeDB) but we still looked for confirmation of some features such as sialic acids manually. It
was possible to confirm the sialic acid in all cases. All the annotated spectra are provided in S1
Supplementary Annotated Spectra.
Further statistical analysis
All glycopeptide ions quantified were used for self organizing maps (SOM) clustering as
described in methods. This clustering gave all cases clustered into two classes at the ends of the
clustered space while all controls were in between (Figure B in S1 File). One case sample (Case
10) was found to be mixing with the controls. We then extracted the data for the identified N-
glycopeptides from the main table and used it to perform the PCA only with this data. The
PCA for identified ions gave us superior separation of the cases and controls (Fig 5).
We then used SOM clustering on the data of identified glycopeptides which is presented in
Fig 6.
The SOM analysis for identified glycopeptides was able to cluster cases and controls sepa-
rately and separation was near complete. Classical hierarchical clustering gave us similar
results (Figure C in S1 File). However, S-Plot significant ions (Table B in S2 File) were able to
best separate the cases and controls in PCA (Figure A in S1 File). We further calculated area
under the curve values (AUC) for these identified 24 N-glycopeptides. Only 4 identified N-gly-
copeptides had AUC values less than 0.7, most others had AUC values of 0.8 and higher and
some of them had AUC values of 0.9 or higher (Table 1).
Discussion
Procalcitonin (PCT) alone, and also in combination with C-reactive protein (CRP) has been
long recognized as a marker of the systemic inflammatory response to bacterial infections[4,
Quantitative N-glycoproteomics of bacteremia plasma
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19]. However several studies have shown that PCT and CRP are not sensitive and/or specific
enough to diagnose bacteremia or to differentiate it from other systemic inflammatory
responses[7–9, 20]. Blood culture is still preferred to make a confirmed diagnosis, however
Table 1. Identified N-glycopeptides. m/z values of the N-glycopeptides, cgharrge, Uniport Id, peptide mass, N-glycosylation site, peptide sequence, Glycan composition,
porposed annotated structure, N-glycopeptide scores and area under the curve (AUC) values from Receiver operating curve analysis of these N-glycopeptides are given in
the table. Where a structure was not matched with database and was elucidated de novo, it is written as denovo (see methods and references therein for more details).
m/z Charge Protein Uniprot
Id
Peptide_Mass N_site Peptide Sequence Glycan
composition
Proposed
Glycan
Structure
Score AUC from
ROC curve
analysis
990.9476 4 A1AT_HUMAN 1754.888 271 YLGNATAIFFLPDEGK S2H5N4 SHNH(SHNH)
HNN
77.59 0.860
1011.432 4 A1AT_HUMAN 1754.888 271 YLGNATAIFFLPDEGK S2H3N6 denovo 44.72 0.857
1320.927 3 A1AT_HUMAN 1754.888 271 YLGNATAIFFLPDEGK S2H5N4 SHNH(SHNH)
HNN
70.66 0.884
1068.449 4 CERU_HUMAN 1891.834 138 EHEGAIYPDNTTDFQR H5N7F1 denovo 40.55 0.774
1067.238 5 CGAT1_HUMAN 2316.176 324 AANFRNFTFIQLNGEFSRGK S2H10N4 denovo 28.54 0.782
903.1394 4 HEMO_HUMAN 1403.674 187 SWPAVGNCSSALR S2H5N4 SHNH(SHNH)
HNN
51.02 0.568
939.653 4 HEMO_HUMAN 1403.674 187 SWPAVGNCSSALR S2H5N4F1 SHNH(SHNH)
HN(F)N
46.03 0.753
985.9345 4 HEMO_HUMAN 1734.885 453 ALPQPQNVTSLLGCTH S2H5N4 SHNH(SHNH)
HNN
39.93 0.787
1203.814 3 HEMO_HUMAN 1403.674 187 SWPAVGNCSSALR S2H5N4 SHNH(SHNH)
HNN
77.43 0.596
932.0305 5 HPT_HUMAN 1794.004 241 VVLHPNYSQVDIGLIK S3H6N5 SHNH(SHN
(SHN)H)HNN
39.03 0.887
1092.015 4 HPT_HUMAN 1794.004 241 VVLHPNYSQVDIGLIK S2H6N5 SHNH(SHN
(HN)H)HNN
39.04 0.764
1115.226 3 HPT_HUMAN 1794.004 241 VVLHPNYSQVDIGLIK S1H4N3 SHNH(H)
HNN
58.34 0.900
1225.552 4 HPT_HUMAN 1794.004 241 VVLHPNYSQVDIGLIK S2H10N3F2 denovo 42.13 0.641
1333.97 3 HPT_HUMAN 1794.004 241 VVLHPNYSQVDIGLIK S2H5N4 SHNH(SHNH)
HNN
74.33 0.910
916.6563 4 HPTR_HUMAN 1457.726 149,153 NLFLNHSENATAK S2H5N4 SHNH(SHNH)
HNN
64.48 0.868
885.6227 5 IGHA1_HUMAN 2962.604 144 LSLHRPALEDLLLGSEANLTCTLTGLR H4N4 HNH(NH)
HNN
29.79 0.767
976.2765 5 IGHA1_HUMAN 2962.604 144 LSLHRPALEDLLLGSEANLTCTLTGLR S1H5N4 SHNH(HNH)
HNN
36.56 0.618
984.488 5 IGHA1_HUMAN 2962.604 144 LSLHRPALEDLLLGSEANLTCTLTGLR S1H4N5 SHNH(NH)
(N)HNN
54.39 0.789
1016.904 5 IGHA1_HUMAN 2962.604 144 LSLHRPALEDLLLGSEANLTCTLTGLR S1H5N5 SHN(HN)H
(NH)HNN
64.97 0.954
1147.326 4 IGHA1_HUMAN 2962.604 144 LSLHRPALEDLLLGSEANLTCTLTGLR H5N4 HNH(HNH)
HNN
33.31 0.723
1179.592 4 IGHA1_HUMAN 2962.604 144 LSLHRPALEDLLLGSEANLTCTLTGLR S1H4N4 SHNH(NH)
HNN
60.04 0.713
868.048 3 IGHG2_HUMAN 1156.515 176 EEQFNSTFR H3N4F1 NH(NH)HN
(F)N
85.11 0.767
885.1539 4 IGHG2_HUMAN 1638.811 176 TKPREEQFNSTFR S1H4N4F1 SHNH(NH)
HN(F)N
42.52 0.856
989.7621 3 IGHG2_HUMAN 1156.515 176 EEQFNSTFR H4N5F1 NNH(HNH)
HN(F)N
62.53 0.623
https://doi.org/10.1371/journal.pone.0195006.t001
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several factors such as time needed to obtain results, false negative cases, and effect of pre-ana-
lytical variables on result outcomes limit its use[21–23].
Plasma glycoproteins have been shown to change during serious inflammation like sepsis
in intensive care unit patients and in bacteremia[11, 24]. In this study we showed that several
N-glycopeptides differed in bacteremic patients from control patients with non-bacteremic
infections.
There are very early changes in glycosylation of proteins in host plasma and/or serum asso-
ciated with inflammation and infection. It was shown that N-glycosylated receptors are
involved in internalization of some bacterial species[25]. An evidence supported theory has
been proposed that microbes manipulate the host glycosylation machinery to use it to their
advantage[26]. These glycosylation changes can be detected and be used as early glyco-bio-
markers if sufficiently sensitive methodologies of analysis are available. Proteomics can also
identify biomarkers of bloodstream infection as we have previously shown[12] however, N-
glycosylation is more sensitive to changes in physiology and it provides another dimension of
selection for the biomarkers. It has been shown that changes in N-glycosylation determine the
susceptibility to infection and influence the host response[27]. This implies that glyco-bio-
markers of bloodstream infections will have the additional specificity compared to protein bio-
markers which might be elevated in other conditions also. We have shown in the past that it is
possible to quantify and identify intact N-glycopeptides with their peptide sequence, glycan
composition and proposed structures[15–17]. In the current study, this technology was used
Fig 4. Structural features of representative examples of N-glycopeptides. An N-glycopeptide of immunoglobulin-A
(IgA) heavy chain is shown here from which six different glycan compositions were found. Single peptide contained six
different glycan compositions making six types of N-glycopeptides which were all identified from their respective
spectrums. The spectrum of these N-glycopeptides matched to database entries (GlyycomeDB). These structural
diagrams have the linkage specific information removed because it is not possible to infer linkage information (such as α-
and β-glycosidic bonds) from the CID-MS/MS spectrum with currently used search tool. Blue squares are N-
acetylglucosamines, green circles are mannoses, yellow circles are galactoses and purple rotated squares are N-
acetylneuraminic acids (sialic acids).
https://doi.org/10.1371/journal.pone.0195006.g004
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in the setting where blood culture positive and negative patients were analyzed for their N-gly-
copeptide content. We have quantified 368 N-glycopeptide ions from plasma of these patients
and subsequently identified 24 glycopeptides comprehensively for their peptide sequence, gly-
can composition and glycan structures in a targeted manner. These 24 confidently identified
N-glycopeptide belonged to 8 different glycoproteins which are alpha-1-antitryspin, cerulo-
plasmin, Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CGAT1), hemopexin, hap-
toglobin, haptoglobin-related protein and heavy chains of immunoglobulin A and G. For
seven out of these 8 proteins, excluding only CGAT1, we compared the protein levels among
the cases and controls from our previous proteomics study and we found that none of them
were statistically significantly different among cases and controls [12]. However, their N-glyco-
peptides expression levels were statistically significantly different among cases and controls (in
current study) suggesting that N-glycosylation of these proteins is changing between cases and
controls. This also suggests that plasma N-glycoproteomics has the power to provide novel
and different markers of the systemic diseases even when they are not captured by proteomics
alone. These markers can also potentially be more sensitive to early changes.
Fig 5. Principal component analysis. PCA was performed on only the N-glycopeptides ions which were identified
and their peptide sequence, glycan composition and proposed structure was elucidated. This PCA gave us separation
of the cases form controls. Principal component 1 (PC1) is on X-axis and principal component 2 (PC2) is on Y-axis.
Red circles are controls and black circles are controls.
https://doi.org/10.1371/journal.pone.0195006.g005
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A previous study has identified major glycoproteins from plasma samples of sepsis patients
and linked them to the survival status of patients[11]. In this study, N-glycopeptides were
enriched by hydrazide chemistry and released from the matrix by PNGAse-F therefore no
information about glycan composition and/or structure was obtained. Our study reports the
complete information about 24 N-glycopeptides which are shown to change between blood
culture positive and negative status of patients by various statistical methods. These peptides
have been previously identified in sepsis patients[11] other than one peptide of CGAT1 (m/z
1067.198) which was shown to increase 1.8 fold in blood culture positive patients compared to
blood culture negative ones (Table A in S2 File). We have identified that on one peptide of
IgA1, six different type of complex type N-glycans are present on the same site suggesting
Fig 6. Self organizing map (SOM). SOM clustering of the 24 identified N-glycopeptide ions is presented in this figure.
https://doi.org/10.1371/journal.pone.0195006.g006
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moderate amount of microheterogeinity. Three of these N-glycopeptides were present in
higher amounts in blood culture positive patients’ plasma while 3 others had reduced levels in
them (Table A in S2 File). Out of these six N-glycoepptides 4 were sialylated and 2 were non-
sialylated complex type glycans. It is known that patients with an automimmune inflammatory
disorder (Sjo¨gren’s syndrome) have higher levels of sialylated N-glycans on IgA1[28].
Increased sialic acid levels are known to be present during bacterial and viral infections and
these levels support the growth of the microbes[29]. Other glycoproteins identified in our
study were acute phase proteins such as hemopexin, alpha-1-antitrypsin, ceruloplasmin and
haptoglobin. Glycosylation of acute phase proteins changes rapidly in host response to inflam-
mation and infection[30–32]. However, most of these identified acute phase N-glycopeptides
seem to be upregulated in plasma of blood culture positive patients compared to febrile con-
trols (blood culture negative). Further studies on these N-glycopeptides are warranted to cor-
relate their levels to prognosis of bloodstream infected patients and to the blood culture result
outcomes.
Using t-test, these identified glycopeptide levels were significantly different among cases
and controls (Table A in S2 File). Moreover, our panel of identified glycopeptides can separate
the blood culture positive versus negative febrile patients at a very early stage, using PCA and
SOM clustering. Hierarchical clustering also gave similar results. This is a statistical validation
of our results that supervised and unsupervised statistical methods using different algorithms
gave similar results. If we consider only S-plot significant glycopeptides, then SOM clustering
was able to separate the two classes. The reason for us to do so many different analyses was to
check the robustness of the results. Various different methods use different algorithms and if a
result holds true in many of them then its serves as validation of the results. We had also
selected multiple other glycopeptides (149 total including S-plot ions) for identification based
on t-test p values and intensity threshold in samples. We have identified 24 glycopeptide with
high confidence from these 149 ions. This has to be noted that in MS/MS identification of gly-
copeptides requires very high quality spectrum to be interpreted by the specialized search
engines (GlycopeptideId in our case). Low abundant glycopeptides as a result of low amounts
or microheterogeneity are particularly difficult to identify by currently available technology
even though its state-of-the-art. Nevertheless, these 24 identified glycopeptides are able to sep-
arate the cases from controls by various statistical methods. Moreover, PCA analysis of S-Plot
ions was able to separate cases from controls (Figure A in S1 File). Cases were spread more in
PCA space compared to controls which highlights that there is some degree of heterogeneity
in the Cases, in terms of the levels of N-glycopeptides. Early bacteremia cases can be reliably
separated from controls using plasma N-glycopeptide expression levels. This separation sup-
ports and validates our decision to select these 2 groups in the first place and shows promising
clinical utility. It has to be emphasized that these results hold true in a bacterial strain indepen-
dent manner.
We analyzed the identified glycopeptides by ROC curve analysis to see how they could sepa-
rate bacteremic cases from noin-bacteremic controls which gave us different values of area
under the curve (AUC) values (Table 1) for different glycopeptides. The highest AUC of 0.954
was found for the N-glycopeptide (m/z 1016.927) of IgA heavy chain which had the composi-
tion of S1H5N5. Glycosylation of IgA has been known to affect the effector functions of IgA
[33] and it’s only logical that it was increased 5.27 times in confirmed cases of bloodstream
infection. It also had a good p(Corr) value of -0.76 in OPLS-DA S-Plot analysis. Specific hybrid
ELISA test measuring the N-glycosylation of IgA using dual-approach (antibody to capture
IgA and lectins to measure N-glycosylation) could be potentially developed in the future to aid
in clinical diagnosis.
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In summary, all of the identified N-glycopeptides were significantly different between the 2
groups by t-test and many of them had good ROC values (Table 1). Supervised and unsuper-
vised clustering was also able to separate the cases form controls. Ions found to be significant
in S-Plot, ten of which were identified, were able to completely separate the cases and controls
in various statistical analyses. These potential glycopeptide ions (even the ones quantified but
not identified in the current study) are particularly important as they can separate bloodstream
infection from the febrile controls. More importantly, these glycopeptide ions were observed
in bacteremic patients due a variety of different bacteria. We have chosen to do a targeted anal-
ysis as it is well suited to be utilized rapidly by other groups also and future studies can provide
extra layer of validation without the need to identify the N-glycopeptides, which is technically
very challenging. A stringent statistical analysis combined with quantitative N-glycoproteo-
mics is a good combination (with enough sensitivity and specificity) which can provide impor-
tant clinical biomarkers for bloodstream infections which are strain-independent and
therefore clinically more important.
Methods
Patient samples
Patient samples were handled as described in our previous study[12]. Briefly, blood samples
were collected to lithium-heparin tubes from adult febrile patients (age range 53–91, median
age 76 years) coming to the outpatient emergency clinic of Peijas Hospital, Helsinki University
Hospital (Vantaa, Finland). Blood cultures were taken based on clinical suspicion of a serious
infection both from the later confirmed cases and from the febrile controls on the same
grounds. An approval for the study was received from the Ethics Committee of Medical Sci-
ences (HUS 169/13/01/2014) and a written informed consent was obtained from all subjects at
the time of plasma sample collection. Blood culturing was performed by using BacT/ALERT1
FA Plus and BacT/ALERT1 FN Plus blood culture bottles (BioMerieux, Durham, NC, USA)
and BacT ALERT 3D incubator (BioMerieux). Identification of bacteria in positive blood cul-
tures was done by Vitek MS MALDI-TOF instrument (bioMerieux). For proteomic analyses
blood samples (3–5 ml) were adjusted to room temperature for 15 min. Subsequently, plasma
was separated by centrifugation (1200xg) for 10 minutes at room temperature. Plasma samples
were stored at -70˚C until tested at the same time.
Trypsin digestion
The complete protocol used in the study has been submitted to the protocols.io with the fol-
lowing doi (10.17504/protocols.io.ncadase). Albumin was removed from plasma samples
according to manufacturer’s instructions (Pierce, Thermo Fisher). BCA assay was used for
protein concentration measurement. After drying, plasma sample volume equivalent to 350μg
of protein, 7μg of bovine Fetuin protein was added and samples were trypsin digested as
described previously[16]. Briefly, 10mM DTT (final concentration) was added to the samples
and incubated for 1 Hour at RT with shaking. Subsequently, 40mM (final concentration) of
Iodoacetamide was added and samples were again incubated at RT for 1 hour with shaking in
dark. 40mM DTT was further added to avoid overalkylation by Iodoacetamide. Seven μg of
bovine pancreatic trypsin was added to the solution and incubated at 37˚C overnight. 60 μL of
tryptic peptides were diluted by 540 μL of 10mM HEPES buffer pH 7.4 containing 1mM
CaCl2 and 1mM MnCl2. this 600 μL mixture was applied to lectin-agarose columns. Briefly,
Con-A: SNA: LCA: AAL were used in ratio of 5:3:3:1 for a final volume of lectin resin slurry of
150 μL. micro-columns containing lectin resins mixed with samples were incubated at 4˚C on
rotation overnight. Next day, three washes with HEPES buffer was performed and N-
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glycopeptides were eluted with sugar-mix solution containing fucose, α-methyl mannoside, α-
methyl glucoside and lactose followed by second elution with 1% formic acid. N-glycopeptides
were cleaned by C18 micro-columns according to manufacturer’s instructions. Resulting N-
glycopeptides were dissolved in 0.1% formic acid before being analyzed by UPLC-MS.
UPLC-MS
A Waters SYNAPT G2 High Definition MS connected to a Waters nanoACQUITY UPLC was
used for the analysis. Positive mode with sensitivity mode was used for MSE (100–2000 Da
mass range) and FAST DDA (positive and sensitivity) mode for N-glycopeptide fragmentation
(50–2500 Da mass range). For MSE, the scan time was 1 second and trap collision energy
(high energy function) was ramped from 14 to 44 V. For FAST DDA experiment, the scan
time was 1 second for MS and MS/MS. Continuum data format and deisotope peak selection
was applied. No exclusion criterion was applied and for inclusion, targeted N-glycopeptide m/
z values were supplied as include files. Mass window for peak inclusion was 250 mDa and
retention time window was 10 seconds. Trap collision energy was applied with low mass to
high mass ramp from 20 to 60 V. Calibration was performed with sodium formate. The trap-
ping column was a nanoACQUITY UPLC Trap, 180 μm x 20 mm (5 μm), Symmetry1C18,
and the analytical column was a nanoACQUITY UPLC, 75 μm x 100 mm (1.8 μm), HSS T3.
Samples were loaded, trapped and washed for two minutes with 8.0 μL/min with 1% B. The
analytical gradient used is as follows: 0–1 minutes 1% B, at 2 minutes 5% B, at 45 minutes 30%
B, at 48 minutes 50% B, at 50 minutes 85% B, at 53 minutes 85% B, at 54 minutes 1% B and at
60 minutes 1% B with 450nL/min for MSE while 300 nL/min for N-glycopeptide
fragmentation.
Data analysis
The raw files were imported to Progenesis QI for proteomics software (Version V2, Nonlinear
Dynamics, Newcastle, UK) using lock mass correction with 785.8426 m/z, corresponding to
doubly charged Glu1-Fibrinopeptide B. Default parameters for peak picking and alignment
algorithm were used. The software facilitated the label-free quantification. Known amount of
bovine Fetuin added to the samples before trypsin digestion allowed the normalization of N-
glycopeptides by known bovine Fetuin N-glycopeptides. Briefly, the Progenesis QI for Proteo-
mics software functions in the following way
Run alignment. The run with the most features (ions) is used as reference and all other
runs are aligned to the reference.
Peak picking. An aggregate data set is created from the aligned runs, which contains all
peak information from all sample files. This aggregate peak list is then matched to each
sample.
Ion abundance quantification. Peptide ion abundance is a sum of areas which is calcu-
lated using intensities of the peaks of a peptide ion’s and peaks’ width.
Subsequent to these steps a filter is applied and we select +3 to +5 charged ions as potential
N-glycopeptides. Thereafter, the groups are compared to show differences in cases vs controls
and as a last step, MS/MS is performed to identify the N-glycopeptides.
N-glycopeptide ions were identified as previously described[15]. Briefly, the MS/MS spectra
were deconvoluted in MaxEnt3 module of Waters MassLynx 4.1 software and saved as peak
lists (.pkl). Identification of N-glycopeptides was performed on the publicly available software
GlycopeptideID, which can perform automated CID MS/MS spectrum analysis. The principle
of this method is explained in detail in our previous publications[15–17]. Briefly, a database of
tryptic peptides (Uniprot, 2 misscleavges allowed, mandatory to have NXS/T/C, P! in the
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peptide sequence, where X is any amino acid other than proline) from known human proteins
is used, and the combined and deconvoluted MS/MS spectra are imported as .pkl files. Soft-
ware matches the MS2 spectra against a peptide database (specified above) and scores potential
peptide backbones. Next, it searches glycan compositions against a glycan database and returns
glycan compositions which are fitted onto the spectrum (glycan score). The glycopeptide score
is the sum of the peptide and glycan scores. The results are ranked, and for each potential
result, an annotated spectrum is drawn for manual assessment of the matching y and b ions,
glycan fragments and glycopeptide fragments. The target-decoy search approach is employed
to calculate false-discovery rate (FDR). The decoy database was generating by reversing the
peptide sequences of tryptic peptide database specified above.
The GlycopeptideId search algorithm has two main steps: i) scoring possible peptide back-
bones by matching the MS2 spectra against a peptide database, and ii) scoring the MS2 spectra
against the glycans which match to the precursor–peptide mass difference. The outcome is a
list of the best matching glycopeptides for each precursor. The results are ordered by the total
score which is related to the (binomial) probability that a similar match could be achieved by
random sampling. Score to a theoretical glycopeptide is defined as a negative logarithm of a
probability that the measured spectrum will have equal or more shared peaks with a random
set of fragments. The probability PR that the random spectrum R has more or equal shared
peaks than the glycopeptide spectrum G is integrated into the formula as Score = −log(PR).
The score defined here is related to the concept of “Ascore” which has been used for phosphor-
ylation site determination [34].
GlycopeptideID gives glycan compositions as one-letter abbreviations H: Hexose, N: Hexosa-
mine, S: Sialic acid, and F: Fucose, and the number following indicates the amount of the mono-
saccharides. Accordingly, S2H6N5 stands for a glycan containing two sialic acids, six hexoses,
and five hexosamines. The glycan structure output format in the GlycopeptideID is a simplified
version of the consortium for functional genomics (CFG) Modified IUPAC condensed format
(www.functionalglycomics.org/static/consortium/Nomenclature.shtml). The stereoisomer (α, β)
and the regioisomer (for ex. 1–4) notations are omitted and the long monosaccharide names are
replaced by single letter codes (H:Hex, N:HexNAc, F:Fuc, S:NeuAc). This format consists of lin-
ear glycan sequences with branching shown by parenthesis and written from nonreducing to
reducing end. As an example a core fucosylated, complex N-glycan with two branches shown in
CFG format as NeuAcα 2-6Gal β 1-4GlcNAc β 1-2Man α 1-6(NeuAcα 2-6Gal β 1-4GlcNAc β 1-
2Man α 1–3)Manβ 1-4GlcNAc β 1-4(Fucα 1–6)GlcNAc-Asn is written as SHNH(SHNH)HN(F)
N. This format is simpler and has a compact notation and it only shows that information which
can be identified with the current experimental technology. for exmaple it does not say anything
about the nature of the glycosidic bond (α or β).
Statistical analysis
Principal component analysis was done in three different softwares namely, Progenesis, R
programming and PAST3.0. Orthogonal projections to latent structures-discriminant anal-
ysis (OPLS-DA) modeling, which generated the S-Plot was performed in EZInfo 3.0. In R,
PCA was performed on scaled data using prcomp R function. Self-Organizing map cluster-
ing was performed on data consists of X number of samples using R package SOM with
parameters (.xdim = 5, ydim = 6, topol = "hexa", neigh = "gaussian") Before performing clus-
tering, data was centered and scaled. SOM provides better visualisation of complex data and
is robust enough to tackle minor experimental variation. Subsequently heatmap was gener-
ated using parameters from hclust function in R. Hierarchical clustering based dendrogram
was generated in PAST3.0.
Quantitative N-glycoproteomics of bacteremia plasma
PLOS ONE | https://doi.org/10.1371/journal.pone.0195006 March 29, 2018 14 / 17
"The mass spectrometry N-glycoproteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE [35] partner repository with the dataset identifier
PXD009048".
Supporting information
S1 File. This file contains supplementary Figures A-C. Figure A shows N-glycopeptides ions
found to be significantly different between the 2 patients classes were used for running princi-
pal component analysis using the publicly available software PAST3.0. 1b-10b are cases while
11b-20b are controls. Figure B shows Self organizing maps clustering performed on all quanti-
fied potential N-glycopeptide ions. Cases and controls can be seen with magnification at the
bottom of the figures. Figure C shows classical hierarchical clustering based on only the identi-
fied N-glycopeptide ions. Triplicate run values were used which also show that all triplicates
cluster together for each sample indicating superior chromatographic alignment.
(PDF)
S2 File. This file contains Table A with all the quantified potential N-glycopeptide ions and
Table B with significantly different potential N-glycopeptide ions found by Orthogonal projec-
tions to latent structures-discriminant analysis visualized by S-Plot.
(XLSX)
S1 Supplementary Annotated Spectra. Annotated spectra for all identified N-glycopeptide
ions.
(PDF)
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